The Valley Desk

Case reportAnnals of hematologyPublished

Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Case report
Venue
Annals of hematology
Published
Subject terms
Humans; Niacinamide; Pyrazoles; Fusion Proteins, bcr-abl; Protein Kinase Inhibitors; Treatment Outcome; Drug Resistance, Neoplasm; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Cytopenia; Tyrosine Kinase Inhibitors (Tkis); Asciminib; Subtherapeutic Dosing
PubMed ID
40192757
PubMed Central ID
PMC12141399
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal